Literature DB >> 17509190

Towards a more physiological approach to IVF.

Geeta Nargund1, René Frydman.   

Abstract

The International Society for Mild Approaches in Assisted Reproduction (ISMAAR) is founded to promote a more physiological, less drug-oriented, lower risk, less expensive and more patient friendly approach to Assisted Reproduction embracing not only natural cycle treatment but also gentle stimulation protocols and in-vitro maturation of oocytes. Recent research suggests that IVF in modified natural cycle/mild stimulation with antagonist is likely to replace the current conventional approach in down-regulated cycles. The Society will focus both on the basic science and clinical aspects of assisted reproduction. It will be committed to promoting international multi-centre scientific research, regular practical workshops for training and also seminars for educating assisted reproduction technology professionals. ISMAAR aims to establish a direct dialogue with the voluntary sector and politicians to campaign for IVF to be a safer, softer and affordable treatment globally.

Entities:  

Mesh:

Year:  2007        PMID: 17509190     DOI: 10.1016/s1472-6483(10)61043-7

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  11 in total

1.  Mild IVF using GnRH agonist long protocol is possible: comparing stimulations with 100 IU vs. 150 IU recombinant FSH as starting dose.

Authors:  Sylvia Fernández-Shaw; Nuria Pérez Esturo; Rosa Cercas Duque; Isabel Pons Mallol
Journal:  J Assist Reprod Genet       Date:  2009-01-17       Impact factor: 3.412

2.  Differences in cumulus cells gene expression between modified natural and stimulated in vitro fertilization cycles.

Authors:  Tanja Burnik Papler; Eda Vrtačnik Bokal; Klementina Fon Tacer; Peter Juvan; Irma Virant Klun; Rok Devjak
Journal:  J Assist Reprod Genet       Date:  2013-11-13       Impact factor: 3.412

3.  ISMAAR: Leading the global agenda for a more physiological, patient-centred, accessible and safer approaches in ART.

Authors:  Geeta Nargund; R C Chian
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

4.  A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.

Authors:  Alberto Revelli; Gianluca Gennarelli; Marta Sestero; Stefano Canosa; Andrea Carosso; Francesca Salvagno; Giulia Pittatore; Claudia Filippini; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2020-03-18       Impact factor: 3.412

5.  High-response intrauterine insemination cycles converted to low-cost in vitro fertilization.

Authors:  Fatma Aletebi
Journal:  J Multidiscip Healthc       Date:  2011-05-10

6.  Low dose of rFSH [100 IU] in controlled ovarian hyperstimulation response: a pilot study.

Authors:  Caio Parente Barbosa; Emerson Barchi Cordts; Andrea Couto Costa; Renato de Oliveira; Marina Acosta de Mendonça; Denise Maria Christofolini; Bianca Bianco
Journal:  J Ovarian Res       Date:  2014-01-21       Impact factor: 4.234

7.  A successful pregnancy following 'double rescue' egg retrieval in a woman with Natural cycle IVF.

Authors:  G Nargund; R-C Chian; S Campbell
Journal:  Facts Views Vis Obgyn       Date:  2014

8.  Comparison of results of cycles treated with modified mild protocol and short protocol for ovarian stimulation.

Authors:  F Coelho; L F Aguiar; G S P Cunha; N Cardinot; E Lucena
Journal:  Int J Reprod Med       Date:  2014-08-06

9.  Declining birth rate in Developed Countries: A radical policy re-think is required.

Authors:  G Nargund
Journal:  Facts Views Vis Obgyn       Date:  2009

10.  The use of in vitro maturation in stimulated antagonist in vitro fertilization cycles of normo-hyperresponder women due to arrested follicular development: A rescue procedure.

Authors:  Şafak Hatırnaz; Süleyman Akarsu; Ebru Saynur Hatırnaz; Ahmet Zeki Işık; Michael Haim Dahan
Journal:  Turk J Obstet Gynecol       Date:  2018-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.